Problems of vaccination and ways to optimize it: a review of randomized clinical trials evaluating Anaferon for children

Abstract

In this article, we discuss the problem of improving vaccination efficacy in children using an antiviral drug with an immunomodulatory effect Anaferon for children produced in Russia. We analyzed the results of randomized clinical trials (RCTs) evaluating the efficacy and safety of Anaferon for children during vaccination against influenza and pneumococcal infection, including that in children with frequent respiratory infections. According to RCT, Anaferon for children used for the prevention of acute respiratory viral infections (ARVI) in combination with specific immunoprophylaxis of influenza and pneumococcal infection, increased the vaccination coverage by reducing the frequency of ARVI episodes before vaccination period and facilitating the development of an adequate immune response after vaccination. Anaferon for children also demonstrated a good safety profile. We described the schemes of ARVI/influenza prevention: 1 tablet a day for 2–4 weeks before vaccination with possible continuation after vaccination for up to 3 months, depending on the clinical situation during the development of active immunity. The results of RCTs and many years of experience allow us to recommend Anaferon for children combination with specific immunoprophylaxis to optimize the vaccination campaign, especially in children with low resistance to infections. It is particularly important during the pandemic of new coronavirus infection. Key words: vaccination, Anaferon for children, prevention, acute respiratory viral infections